<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39331196</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1573-2592</ISSN><JournalIssue CitedMedium="Internet"><Volume>45</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Journal of clinical immunology</Title><ISOAbbreviation>J Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>Health Care Utilisation in a Cohort of Patients with Primary and Secondary Antibody Deficiency in the United Kingdom.</ArticleTitle><Pagination><StartPage>18</StartPage><MedlinePgn>18</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">18</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10875-024-01809-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">This study investigates the frequency of hospital attendances, emergency care attendances and geographical influences on service interaction in cohorts of patients with primary and secondary antibody deficiency, to inform future service planning and delivery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The COVID-19 in Antibody Deficiency (COV-AD) study was a United Kingdom study that enrolled 525 participants between April 2021 and September 2022. Data on health care utilisation was extracted from a screening cohort of participants at one participating site (Birmingham, UK). Hospital attendance (i.e. all outpatient and inpatient care episodes, including hospital-based IVIG treatment) and emergency care attendance patterns were analysed. Geographical differences in travel times to hospitals and associated costs were considered for all participants at all recruiting sites.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Individuals with antibody deficiency had a median of 7 hospital attendances per year. A diagnosis of secondary antibody deficiency, and antibody deficiency severe enough to require treatment with immunoglobulin replacement were associated with an increased frequency of hospital attendance. 12.7% of the cohort attended the Emergency Department at least once in the preceding twelve months. Individuals with secondary antibody deficiency were at greater risk of requiring emergency care over the preceding one-year and five-year periods. Individuals receiving subcutaneous immunoglobulin lived further from their local immunology centre and were more likely to engage with the COV-AD research study remotely, via dried blood spots sampling.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study highlights the utilisation of emergency and secondary care usage amongst patient with immunodeficiency and may inform service adaptation and development to better accommodate patient needs and circumstances.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dimbleby</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenway</LastName><ForeName>Will</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Siobhan O</ForeName><Initials>SO</Initials><AffiliationInfo><Affiliation>Department of Immunology, Royal Free London NHS Foundation Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Immunity and Transplantation, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Alex G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shields</LastName><ForeName>Adrian M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Clinical Immunology Service, School of Infection, Inflammation and Immunology, University of Birmingham, Birmingham, UK. a.m.shields@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Immunology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. a.m.shields@bham.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Immunol</MedlineTA><NlmUniqueID>8102137</NlmUniqueID><ISSNLinking>0271-9142</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="Y">Patient Acceptance of Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007153" MajorTopicYN="N">Immunologic Deficiency Syndromes</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="N">Emergency Service, Hospital</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Healthcare Resource use</Keyword><Keyword MajorTopicYN="N">Inborn Errors of Immunity</Keyword><Keyword MajorTopicYN="N">Primary Immunodeficiency</Keyword><Keyword MajorTopicYN="N">Rare Disease</Keyword><Keyword MajorTopicYN="N">Secondary Immunodeficiency</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331196</ArticleId><ArticleId IdType="pmc">PMC11436396</ArticleId><ArticleId IdType="doi">10.1007/s10875-024-01809-3</ArticleId><ArticleId IdType="pii">10.1007/s10875-024-01809-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Krishna MT, et al. The impact of COVID-19 Pandemic on Adult and Pediatric Allergy &amp; Immunology Services in the UK National Health Service. J Allergy Clin Immunol Pract. 2021;9(2):709–e7222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703386</ArticleId><ArticleId IdType="pubmed">33271350</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields AM et al. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the United Kingdom. Clinical and Experimental Immunology, 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8807296</ArticleId><ArticleId IdType="pubmed">35641155</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponsford MJ, et al. A systematic review and Meta-analysis of Inpatient Mortality Associated with Nosocomial and Community COVID-19 exposes the vulnerability of immunosuppressed adults. Front Immunol. 2021;6(12):7446961664–3224. (Electronic)).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8526940</ArticleId><ArticleId IdType="pubmed">34691049</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulvirenti F, et al. Health-Related Quality of Life in Common Variable Immunodeficiency Italian patients switched to Remote Assistance during the COVID-19 pandemic. J Allergy Clin Immunol Pract. 2020;8(6):1894–e18992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195351</ArticleId><ArticleId IdType="pubmed">32278865</ArticleId></ArticleIdList></Reference><Reference><Citation>Grigoriadou SA, et al. British Society for Immunology and United Kingdom Primary Immunodeficiency Network (UKPIN) consensus guideline for the management of immunoglobulin replacement therapy. Clin Exp Immunol. 2022;210:1–13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9585546</ArticleId><ArticleId IdType="pubmed">35924867</ArticleId></ArticleIdList></Reference><Reference><Citation>Elhaj MO, et al. Dose reductions in immunoglobulin replacement are associated with increased antibiotic usage in patients with antibody deficiency. Br J Haematol. 2023;202(4):900–3.</Citation><ArticleIdList><ArticleId IdType="pubmed">37339874</ArticleId></ArticleIdList></Reference><Reference><Citation>Richards N. The impact of remote care on burden of treatment. BMJ 2022 Jun 27:37701579.</Citation><ArticleIdList><ArticleId IdType="pubmed">35760424</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields AM et al. SARS-CoV-2 vaccine responses in individuals with antibody Deficiency: findings from the COV-AD study. J Clin Immunol, 2022: pp. 1–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9008380</ArticleId><ArticleId IdType="pubmed">35420363</ArticleId></ArticleIdList></Reference><Reference><Citation>Alligon M, et al. An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: a study of a national retrospective cohort of 1375 patients over 10 years. J Allergy Clin Immunol. 2022;149(6):2216–2125.</Citation><ArticleIdList><ArticleId IdType="pubmed">35031273</ArticleId></ArticleIdList></Reference><Reference><Citation>Mustafa Ali MK, et al. Hospital admissions secondary to diseases of the blood, blood-forming organs, and Immune System in England and Wales. Cureus. 2022;14(10):e30179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648385</ArticleId><ArticleId IdType="pubmed">36397897</ArticleId></ArticleIdList></Reference><Reference><Citation>Coignard-Biehler HA, et al. A 1-Year prospective French Nationwide Study of Emergency Hospital Admissions in children and adults with primary immunodeficiency. J Clin Immunol. 2019;37(7):702–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">31401750</ArticleId></ArticleIdList></Reference><Reference><Citation>Gholami K, et al. Costs of Hospital Admission on Primary Immunodeficiency diseases. Iran J Public Health. 2017;46(3):342–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5395530</ArticleId><ArticleId IdType="pubmed">28435820</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields AM, et al. Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. Front Immunol. 2022;13:984376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539662</ArticleId><ArticleId IdType="pubmed">36211396</ArticleId></ArticleIdList></Reference><Reference><Citation>Shields AM, et al. Clinical and laboratory characteristics of patients with symptomatic secondary immunodeficiency following the treatment of haematological malignancies. EJHaem. 2023;4(2):339–49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10188475</ArticleId><ArticleId IdType="pubmed">37206270</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie B, et al. Economic impact of self-administered subcutaneous versus clinic-administered intravenous immunoglobulin G therapy in Alberta, Canada: a population-based cohort study. Allergy Asthma Clin Immunol. 2022;18(1):99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9700869</ArticleId><ArticleId IdType="pubmed">36434668</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin A, et al. Economic benefits of subcutaneous rapid push versus intravenous immunoglobulin infusion therapy in adult patients with primary immune deficiency. Transfus Med. 2013;23(1):55–60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3580879</ArticleId><ArticleId IdType="pubmed">23167310</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsina L, et al. Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain. Eur J Health Econ. 2022;23(3):551–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8964571</ArticleId><ArticleId IdType="pubmed">34546485</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel SY, Carbone J, Jolles S. The Expanding Field of secondary antibody Deficiency: causes, diagnosis, and management. Front Immunol. 2019;10:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6376447</ArticleId><ArticleId IdType="pubmed">30800120</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron U et al. Epigenetic immune cell counting in human blood samples for immunodiagnostics. Sci Transl Med, 2018. 10(452).</Citation><ArticleIdList><ArticleId IdType="pubmed">30068569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferentinos P, et al. Validation of dried blood spot sampling for detecting SARS-CoV-2 antibodies and total immunoglobulins in a large cohort of asymptomatic young adults. J Immunol Methods. 2023;518:113492.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10185490</ArticleId><ArticleId IdType="pubmed">37201783</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>